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Purpose: Cryptococcal meningitis is a relatively common opportunistic infection 
in human immunodeficiency virus (HIV) patients and it can frequently occur in im-
munocompetent hosts without any apparent underlying disease. Nevertheless, little 
is known about cyptococcal meningitis in the Korean population. The purpose of 
this study was to evaluate the clinical features and initial laboratory findings of 
cryptococcal meningitis in patients with and without HIV at a tertiary care teaching 
hospital. Materials and Methods: We performed a retrospective study at a tertiary 
care teaching hospital from January 2001 to December 2009. Eleven HIV positive 
patients and nine HIV negative patients were included. Results: The most common 
symptoms were headache and fever in cryptococcal meningitis, and diabetic melli-
tus, end stage renal disease and liver cirrhosis were the main associated conditions 
in patients without HIV. Patients with HIV showed lower peripheral CD4+ cell 
counts (median: 9, range: 1-107) and a higher burden of cryptococcus than patients 
without HIV. There were no statistically significant differences in serum CRP level 
and other cerebrospinal fluid parameters between patients with HIV and without 
HIV. The in-hospital mortality was 10%, and recurrence of cyptococcal meningitis 
was observed in 3 patients with HIV and this occurred within 5 months of the first 
episode. Conclusion: Cryptococcal meningitis is fatal without treatment, therefore, 
rapid recognition of symptoms such as fever and headache and diagnosis is re-
quired to decrease the mortality. Recurrence of meningitis after treatment should 
carefully be followed up, especially in advanced HIV patients. 
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INTRODUCTION
Cryptococcus neoformans is an ubiquitous encapsulated yeast that causes signifi-
cant infections, which range from asymptomatic pulmonary colonization to life 
threatening meningoencephalitis.1
Cryptococcosis occurs among immunocompromised hosts due to one of the fol-
lowing conditions: human immunodeficiency virus (HIV) infection, prolonged 
treatment with glucocorticoids, organ transplantation, malignancy, sarcoidosis, and 
in immunocompetent hosts who are without any apparent underlying condition.2,3 Cryptococcal Meningitis in Patients with or without Human Immunodeficiency Virus
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tis were treated according to the practice guidelines for the 
management of cryptococcal disease.9 The patients with 
HIV received amphotericin B 0.7 mg/kg+flucytosine 400 
mg/kg per day followed by fluconazole 200 mg per day, 
and the patients without HIV received amphotericin B 0.5 
mg/kg/day followed by fluconazole 200 mg per day. 
The median treatment duration of amphotericin B was 
32.2 days (range: 11-80), and median duration of flucon-
azole was 110 days (range: 28-695) in this study. 
Statistical analysis
Statistical analysis was done using SPSS version 12.0 (SPSS 
Corp, Chicago, IL, USA). The descriptive analysis consist-
ed of the median and range for various parameters. The ini-
tial laboratory findings between the patients with and without 
HIV were compared using the chi-square test for categorial 
variables, t-test or ranksum test for numerical variables. p 
values <0.05 were considered to be statistically significant.
RESULTS
Demographic features and clinical outcomes
The demographics, clinical outcomes and treatment of the 
patients with or without HIV are shown in Table 1.
Twenty patients who were diagnosed with cryptococcal 
meningitis were analyzed. The median age was 47.5 years 
(range: 25-73 years). Fifteen patients (75%) were men and 
five patients (25%) were women. All the HIV positive pa-
tients (n=11) were men. There were 11 (55%) and 9 (45%) 
patients with HIV and without HIV, respectively. 
The underlying conditions in the patients without HIV 
were idiopathic CD4 lymphocytopenia (n=1; 11.1%), dia-
betes mellitus (n=3; 33.3%), end stage renal disease (n=2; 
22.2%), liver cirrhosis (n=2; 22.2%), and interstitial lung dis-
ease with steroid use (n=1; 11.1%), and four patients (44.4%) 
had no apparent underlying disease at the time of diagnosis 
of cryptococcal meningitis. Mycobacterium infection (n=3; 
27.3%), pneumocystis (carinii) jiroveci pneumonia (PCP) 
(n=4; 36.4%), kaposi sarcoma (n=1; 9%) and liver cirrhosis 
(n=1; 9%) were concurrently observed in the patients with 
HIV; pneumocystis (carinii) jiroveci pneumonia (PCP) was 
associated with 2 patients (22.2%) without HIV. 
Eleven patients with HIV were studied. Their median HIV 
RNA titer was 111,000 copies/mL (from 323 to 337,000). 
The CD4 cell count ranged from 1 to 107 cells/µL. The me-
dian CD4 cell count was 9.5 cells/uL. Cryptococcal menin-
The most common sites of infection are the central nervous 
system and lungs.1-3 C. neoformans infection occurs follow-
ing inhalation through the respiratory tract. The organism 
disseminates hematogenously and has a propensity to local-
ize to the central nervous system, causing meningitis/me-
ningoencephalitis.4,5 Although the incidence of cryptococcal 
meningitis has declined in HIV patients who are undergoing 
antiretroviral therapy, cryptococcal disease remains a lead-
ing cause of mortality in the developing world.6 C. neofor-
mans usually infects HIV infected patients with CD4 T lym-
phocytes counts <100 cells/µL. The burden of organisms is 
generally higher, and the inflammatory response is much 
less in HIV infected patients than in non HIV infected pa-
tients. On the other hand, patients without HIV infection 
usually have a longer duration of symptoms, higher cere-
brospinal fluid (CSF) cell counts, lower glucose levels and 
a lower burden of organism than do the patients with HIV 
infection.7,8
This infection is fatal without treatment. Therefore, rapid 
recognition, diagnosis and treatment are required to de-
crease the mortality. However, little is known about crypto-
coccal meningitis in the Korean population. We report here-
in our experience of cryptococcal meningitis and evaluation 
of the clinical features and initial laboratory findings of 
cryptococcal meningitis in patients with and without HIV.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of patients 
with cryptococcal meningitis and who were admitted to Pu-
san National University Hospital, Busan, South Korea, 
from January 2001 to December 2009. Cryptococcal men-
ingitis was defined as the clinical features of meningitis/
meningoencephalitis along with a positive CSF cryptococ-
cal antigen test or a positive CSF India ink preparation or 
isolation of Cryptococcus neoformans in the CSF cultures. 
HIV infection was confirmed by a combination of ELISA 
and Western blotting. The patients’ demographic data, pre-
disposing condition, presenting symptoms, initial laborato-
ry findings (serum WBC, serum CRP, CSF cryptococcal 
antigen titer, CSF glucose, CSF cell count and cryptoccus 
culture of the blood/CSF), treatments and outcomes were 
included. The CD4+ cell count and plasma viral load, the 
duration of antiretroviral therapy (ART) before cryptococ-
cal meningitis and the ART regimen were checked in the 
patients with HIV. The patients with cryptococcal meningi-Su Jin Lee, et al.
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The most common symptom was headache (n=14; 70%), 
and others were fever (n=10; 50%), altered mentation rang-
ing from confusion to a comatous state (n=8; 40%), general 
weakness (n=5; 25%), dyspnea (n=5; 25%), nausea or vom-
iting (n=3; 15%), dizziness (n=4; 20%), insomnia (n=2; 
10%) and hearing disturbance/tinnitus (n=2; 10%). 
The median number of admission days was 47.5 days 
(range: 5-117). Out of twenty patients, sixteen patients im-
proved with treatment while two patients died and two pa-
tients were transferred to other hospitals. One of the two 
patients who died had high intracranial tension and diffuse 
cerebral edema seen on CT, and the other had acquired hos-
pital pneumonia followed with adult respiratory distress 
syndrome (ARDS). 
gitis was the first AIDS-defining illness in 4 patients (36.4%). 
Other associated conditions were concurrently seen in 8 pa-
tients (72.7%): Mycobacterium infection (n=3; 27.3%), 
PCP (n=4; 36.4%), kaposi sarcoma (n=1; 9%) and liver cir-
rhosis (n=1; 9%) (Table 1). Seven patients received ART at 
presentation. Four of the 7 patients (36.4%) who received 
ART started it within the last six months of the index presen-
tation, one patient (9.1%) received ART for 8 months and the 
other two patients received ART for more than one year be-
fore cryptococcal meningitis. Two patients were receiving a 
combination of lamivudine, zidovudine and lopinavir/lito-
navir, and the other five patients were receiving various 
combinations. The characteristics of the patients with HIV 
are shown in Table 2. 
Table 1. The Demographics and Clinical Outcomes of the 20 Patients with Cryptococcal Meningitis 
Variable
HIV positive (n=11)
No. (%)
HIV negative (n=9)
No. (%)
Total (n=20)
No. (%)
Age (yrs)[median (range)]   48.0 (35-72)   46.5 (25-73)   47.5 (25-73)
Men 11 (100) 4 (44.4) 15 (75.0)
Associated conditions
    Mycobacterium infection (Tbc, NTM )  3 (27.3) 0 (0.0) 3 (15.0)
    PCP 4 (36.4) 2 (22.2) 4 (20.0)
    Kaposi sarcoma 1 (9) 0 (0.0) 1 (5.0)
    Idiopathic CD4 Lymphocytopoenia 0 (0.0) 1 (11.1) 1 (5.0)
    Interstitial lung disease 0 (0.0) 1 (11.1) 1 (5.0)
    Diabetes mellitus 0 (0.0) 3 (33.3) 3 (15.0)
    End stage renal disease 0 (0.0) 2 (22.2) 2 (10.0)
    Chronic Hepatitis (HBV, HCV) 1 (9.0) 2 (22.2) 3 (15.0)
    None 0 (0.0) 4 (44.4) 4 (20.0)
Presenting symptoms
   Headache 6 (54.5) 8 (88.9) 14 (70.0)
   Fever 8 (72.7) 2 (22.2) 10 (50.0)
   Altered mentality 5 (45.5) 3 (33.3) 8 (40.0)
   General weakness 3 (27.3) 2 (22.2) 5 (25.0)
   Dyspnea 4 (36.4) 1 (11.1) 5 (25.0)
   Dizziness  2 (18.2) 2 (22.2) 4 (20.0)
   Insomnia 2 (18.2) 0 (0.0) 2 (10.0)
   Hearing disturbance, Tinnitus 0 (0.0) 2 (22.2) 2 (10.0)
   Nausea or vomiting 2 (18.2) 1 (11.1) 3 (15.0)
Admission days (days)[mean (range)]   39.5 (5-102)   50.5 (31-117)   47.5 (5-117)
Mortality 1 (9.0) 1 (11.1) 2 (10.0)
Transfer to other hospital 1 (9.0) 1 (11.1) 2 (10.0)
Recurrence 3 (27.3) 0 (0.0) 3 (15.0)
Treatment duration of amphotericinB
  (days)[median (range)]
  28.6 (16-42)   48.0 (11-80) p=0.095
Treatment duration of fluconazole
  (days)[median (range)]
  217.0 (40-695)   67.0 (28-108) p=0.018
HIV, human immunodeficiency virus; NTM, nontuberculous mycobacteria; PCP, pneumocystis (carinii) jiroveci pneumonia; HBV, hepatitis 
B virus; HCV, Hepatitis C virus.Cryptococcal Meningitis in Patients with or without Human Immunodeficiency Virus
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teen patients (n=11, 100% in the HIV patients vs. n=7, 
77.8% in the non HIV patients). The patients with HIV had 
lower serum WBC counts (median: 3,800 cell/µL vs. 7,880 
cell/µL; p=0.001) and a higher positivity rate for cryptococ-
cus culture of the blood (45.5% vs. 11.1%, respectively;  p= 
0.046) than the patients without HIV. There were no signifi-
cant differences between the patients with HIV and without 
HIV in the serum CRP (2.02 mg/dL vs. 1.5 mg/dL;  p=0.288) 
and other initial CSF examinations such as CSF glucose 
level (p=0.967), CSF cell counts (p=0.875), cryptococcal 
antigen titer (p=0.621) and positivity rate of cryptococcus 
culture (p=0.656). Comparison of the initial laboratory find-
ings (serum WBC, serum CRP, CSF cryptococcal antigen 
titer, CSF glucose, CSF cell count and cryptoccus culture in 
blood/CSF) of the patients with HIV and without HIV is 
shown in Table 3.
Chest X-ray and cranial CT or MRI were carried out in all 
patients. Eight patients showed abnormal lung lesion. Six 
patients with HIV (4: PCP, 2: pulmonary tuberculosis) and 
Three patients (15%) had recurrence of cryptococcal men-
ingitis. All these patients were HIV positive and recurrence 
occurred within 5 months of the first episode of cryptococ-
cal meningitis. There were no significant differences in 
treatment duration of amphotericin B (median number of 
treatment days: 28.6 days vs. 48 days; p=0.95) between the 
patients with HIV and without HIV. However, duration of 
fluconazole treatment in patients with HIV was longer than 
patients without HIV (median number of treatment days: 
217 days vs. 67 days ;  p=0.018). 
The outcomes of the two transferred patients were not as-
sessed. 
The seven improved patients without HIV were followed 
up for at least 2 months and the nine improved HIV posi-
tive patients were followed up for at least 5 years. 
Initial laboratory findings
The cryptococcal antigen test for the CSF was positive in 
all the patients, and the Indian ink test was positive in eigh-
Table 2. CD4+ count, HIV RNA Titer and ART Treatment of Cryptococcal Meningitis in the Patients with HIV
Variables n (%)
CD4+ count (cell/µL)[median (range)]  9.5 ( -107)
HIV RNA titer (copies/mL )[median (range)]       111,000 (323-337,000)
Duration of ART before CM 
    >1 yr 2 (18.2)
    6-12 months 1 (9.1)
    1-6 months 2 (18.2)
    <1 months 2 (18.2)
    No treatment  4 (36.4)
ART regimen (total 7 patients )
    Zidovudine, lamivudine, Lopinavir/litonavir 2 (28.6)
    Zidovudine, lamivudine, Indinavir 1 (14.3)
    Lamivudine, Stavudine, efavirenz 1 (14.3)
    Lamivudine, Abacavir, atazanavir 1 (14.3)
    Lamivudine, Clexivan 1 (14.3)
    Lamivudine, Efavirenz 1 (14.3)
HIV, human immunodeficiency virus; ART, anti retroviral agent; CM, cryptococcal meningitis. 
Table 3. Initial Laboratory Findings of the Patients with Cryptococcal Meningitis 
Variable HIV positive (n=11) HIV negative (n=9) p values
 Serum WBC (cell/µL)[median (range)]  3,800 (1430-6380) 7,880 (6240-20400) 0.001*
 Serum CRP (mg/dL)[median (range)]   2.02 (0.08-6.71)     1.5 (0.13-19.8) 0.288*
 CSF glucose (mg/dL)[median (range)]      34 (3-63)      31 (10-71) 0.967*
 CSF cell count (cell/µL)[median (range)]    285 (1-286)     150 (6-150) 0.875*
 CSF cryptococcal antigen titer [median (range)]    256 (64-256 )      16 (2-2046) 0.621*
Positive CSF Cryptococcus culture (%)       10 (91.0)        7 (77.8) 0.656
†
Positive Blood Cryptococcus culture (%)        5 (45.5)        1 (11.1) 0.046
†
HIV, human immunodeficiency virus; CSF, cerebrospinal fluid.
*Using ranksum test.
†Using Chi-square test.Su Jin Lee, et al.
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tients (n=11, 100% for the HIV patients vs. n=7, 77.8% for 
the non HIV patients).
Other studies have reported that the sensitivities, specific-
ities and false positivity of the cryptococcal antigen test are in 
the range of 93-100%, 93-98% and approximately 0-0.4%, 
respectively, and the Indian ink test is positive in 70-90% of 
the patients with HIV and in only 50% of the patients with-
out HIV.2,10,13
The CD4+ T cell count is the main predictor of an HIV 
patient’s immunologic state.
Cryptococcal meningitis rarely occurs in patients with a 
CD4+ T cell counts greater than 100/µL. One study report-
ed that average CD4+ T cell counts in patients with HIV 
and cryptococcosis were 73 cells/µL.14 The median CD4+ 
T cell count and range in this case series were 9.5 cells/µL 
and 1-107 cells/µL, respectively. Four of eleven patients 
with HIV were not receiving ART at admission, and cryp-
tococcal meningitis was the first AIDS defining illness in 
those four patients. Although two out of the seven patients 
who were receiving ART had been on ART for more than 
one year before cryptococcal meningitis, these two patients’ 
CD4+ T cell counts were very low at 30 cells/µL and 8 
cells/µL, respectively. Poor compliance with ART is postu-
lated as the cause for this. The in-hospital mortality in this 
case series was 10% (n=2).
Other studies also showed that acute mortality was in the 
range of 6-15%.15-18 The significant clinical and laboratory 
predictors of death during initial therapy include an abnor-
mal mental status, a CSF antigen titer >1 : 1,024 and a CSF 
WBC count <20 cells/µL.8 In our study, the two patients 
who died had low CSF cell counts (<20), and they showed 
altered mentation. However, there was no relationship be-
tween in hospital mortality and the CSF antigen titer in 
these two patients. Although all the patients with HIV were 
treated with fluconazole as maintenance therapy after dis-
charge, recurrence of infection after the initial treatment 
was observed in three patients. These three patients were 
HIV positive and recurrence occurred within 5 months of 
the first episode. Non compliance with taking their medica-
tion was the cause for recurrence in all of these patients.
There are not many studies on cryptococcal meningitis in 
the Korean population. Choi, et al.19 reported fifteen Korean 
patients with cryptococcosis, who were studied from 1974 
to 1983. However, the study presented no data on patients 
with HIV, and included only one patient with cryptococcal 
meningitis. To our best knowledge, this is the first trial that 
studied the characteristics of cryptococcal meningitis in pa-
two patients without HIV (PCP) were observed. In neuro-
imaging, seven patients had abnormal neuroimaging. Three 
patients with HIV showed meningeal enhancement lesion 
and other four patients without HIV showed meningeal en-
hancement lesion (n=1), acute multiple infarction (n=2), 
and multiple intracranial granulomas (n=1). 
DISCUSSION
In this study, the ages of patients were very diverse (median 
47.5 years; range 25-73 years) and men were dominant, es-
pecially in the HIV group. Diabetic mellitus, end stage re-
nal failure and liver cirrhosis were the major risk factors for 
the patients without HIV. However, four patients (20% of 
the total enrolled patients) had no apparent underline dis-
ease, making us to diagnose cryptococcal meningitis diffi-
cult. Fever and headache out of many various symptoms 
were the most common symptoms, which is consistent to 
the earlier reports,2,10,11 while the incidence of altered men-
tation (40% of the total patients and 45.5% of the patients 
with HIV) in our study was higher than that of the other re-
ports (13-25% of patients).11,12 In this report, 25% of the pa-
tients had dyspnea, which could be due to associated pneu-
monia as PCP rather than systemic dissemination. Although 
focal neurologic deficits such as hearing disturbance/tinni-
tus were seen in a small number of patients, these symp-
toms were important. In two patients without apparent un-
derlining disease, focal neurologic deficit was the main 
presentation of cryptococcal meningitis at admission.
Patients without HIV are known to have higher CSF cell 
counts, lower glucose levels and a lower burden of organ-
ism than the patients with HIV.7,8 In this study, most of the 
initial laboratory findings (serum CRP, CSF cryptococcal 
antigen titer, CSF glucose, CSF cell count and cryptoccus 
culture in CSF) had no statistical significance between the 
patients with HIV and the patients without HIV. But, there 
was a higher positive rate of Cryptococcus culture in blood 
in the patients with HIV than that in the patients without 
HIV (45.5% vs. 11.1%, respectively;  p=0.046), indicating 
a higher burden of Cryptococcus in the patients with HIV. It 
is highly possible that these findings were due to small num-
ber of patients. Detection of cryptococcal capsular polysac-
charide antigen and the Indian ink test were important tests 
for diagnosing cryptococcal meningitis in our study: the 
cryptococcal antigen test in CSF was positive for all the pa-
tients and the India ink test was positive for eighteen pa-Cryptococcal Meningitis in Patients with or without Human Immunodeficiency Virus
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tients with or without human immunodeficiency virus in 
the Korean population. 
This study has some limitations. The study was performed 
in a single tertiary hospital by retrospective chart review, and 
enrolled patients number was small. These facts may limit 
generalization of the results to the entire Korean popula-
tion. Further large multicentered studies are required to ob-
tain more accurate data on cryptococcal meningitis in the 
Korean population.
In summary, this study demonstrated that cryptococcal 
meningitis can occur not only in the HIV positive patients 
with low CD4+ cell counts, but also in patients without any 
apparent underlying disease. The most common symptoms 
were headache, fever and altered mentation.
Diabetic mellitus, end stage renal disease and liver cir-
rhosis were the main associated conditions in the patients 
without HIV. Patients with HIV showed very low CD4+ 
cell counts and a higher burden of cryptococcus than did 
the patients without HIV. While there were no statistically 
significant differences in the serum CRP level between the 
patients with and without HIV, other CSF examinations 
(glucose level, cell counts, cryptococcal antigen titer, posi-
tivity rate of cryptococcus culture) did show significant dif-
ferences.
Detection of cryptococcal antigen and the Indian ink test 
were found to be important tools for diagnosis in this study. 
The in hospital mortality was 10%, in agreement with the 
data from other studies. Recurrence was observed in three 
patients with HIV, and this occurred within 5 months of the 
first episode. Non compliance with taking medication was 
the cause for recurrence in all of these patients.
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